VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma

Journal of the National Cancer Institute

Volumn 94, Issue 20, 2002, Pages 1569-1575

  Yao, Masahiro ^a   Yoshida, Minoru ^a   Kishida, Takeshi ^a   Nakaigawa, Noboru ^a   Baba, Masaya ^a   Kobayashi, Kazuki ^a   Miura, Takeshi ^b   Moriyama, Masatoshi ^c   Nagashima, Yoji ^a   Nakatani, Yukio ^d   Kubota, Yoshinobu ^a   Kondo, Kei Ichi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b KANAGAWA CANCER CENTER   (Japan)

^c Yokohama Municipal Hospital   (Japan)

^d YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL STUDY; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GENDER; GENE MUTATION; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NONBIOLOGICAL MODEL; PRIORITY JOURNAL; PROGNOSIS; SOMATIC MUTATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYMPTOM; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0037120977     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.20.1569     Document Type: Article

References (35)

1. Belldegrum, A, deKernion JB. Renal tumors. In: Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ, editors. Campbell's urology. 7th ed. Philadelphia (PA): W. B. Saunders Company; 1998. p. 2283-326.
2. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998;352:1691-6.
3. Zhou M, Rubin MA. Molecular markers for renal cell carcinoma: impact on diagnosis and treatment. Semin Urol Oncol 2001;19:80-7.
4. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183:131-3.
5. Storkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, et al. Classification of renal cell carcinoma: Workgroup No. 1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:987-9.
6. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7:85-90.
7. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, Hosaka M, et al Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852-5.
8. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
9. Brauch H, Weirich G, Brieger J, Glavac D, Rodl H, Eichinger M, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000;60: 1942-8.
10. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinico-pathological parameters, Genes Chromosomes Cancer 2002;34:58-68.
11. Iliopoulos O, Kibel A, Gray S, Kaelin WG Jr. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1995;1:822-6.
12. Chen F, Kishida T, Duh FM, Renbaum P, Orcutt ML, Schmidt L, et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res 1995;55:4804-7.
13. Stebbins CE, Kaelin WG Jr, Pavletich NP. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999;284;455-61.
14. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001;292:464-8.
15. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-72.
16. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075-83.
17. Wiesener MS, Munchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61:5215-22.
18. Tsuchiya H, Iseda T, Hino O. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Cancer Res 1996;56:2881-5.
19. Ohh M, Yauch RL, Lonergan KM, Whaley JM, Stemmer-Rachamimov AO, Louis DN, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998:1:959-68.
20. Okuda H, Hirai S, Takaki Y, Kamada M, Baba M, Sakai N, et al. Direct interaction of the beta-domain of VHL tumor suppressor protein with the regulatory domain of atypical PKC isotypes. Biochem Biophys Res Commun 1999;263:491-7.
21. Cohen HT, Zhou M, Welsh AM, Zarghamee S, Scholz H, Mukhopadhyay D, et al. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem Biophys Res Commun 1999;266:43-50.
22. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997;80:992-3.
23. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
24. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260:1317-20.
25. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-57.
26. Stolle C, Glenn G, Zbar B, Humphrey JS, Choyke P, Walther M, et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat 1999;12:417-23.
27. Cybulski C, Krzystolik K, Maher ER, Richard S, Kurzawski G, Gronwald J, et al. Long polymerase chain reaction in detection of germline deletions in the von Hippel-Lindau tumour suppressor gene. Hum Genet 1999;105: 333-6.
28. Gallou C, Joly D, Mejean A, Staroz F, Martin N, Tarlet G, et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999;13:464-75.
29. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22:200-9.
30. Martinez A, Fullwood P, Kondo K, Kishida T, Yao M, Maher ER, et al. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol 2000;53:137-44.
31. Choyke PL, Glenn GM, Walther MM, Zbar B, Weiss GH, Alexander RB, et al. The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol 1992;159:1229-34.
32. Neumann HP, Bender BU, Berger DP, Laubenberger J, Schultze-Seemann W, Wetterauer U, et al. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma. J Urol 1998;160:1248-54.
33. Yoshida M, Ashida S, Kondo K, Kobayashi K, Kanno H, Shinohara N, et al. Germ-line mutation analysis in patients with von Hippel-Lindau disease in Japan: an extended study of 77 families. Jpn J Cancer Res 2000; 91:204-12.
34. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
35. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-17.